Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers

(MedPage Today) -- The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers. The action represents the...
Source: MedPage Today Public Health - Category: American Health Source Type: news